{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:34:07Z","timestamp":1761896047072},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.semarthrit.2015.04.003","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T05:16:23Z","timestamp":1428729383000},"page":"S16-S21","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S","title":["Inflammatory diseases: Integrating biosimilars into clinical practice"],"prefix":"10.1016","volume":"44","author":[{"given":"Steven R.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.04.003_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3899\/jrheum.091461","article-title":"Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib2","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-203198","article-title":"Biosimilars to treat inflammatory arthritis: the challenge of proving identity","volume":"72","author":"Kay","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrrheum.2012.84","article-title":"The advent of biosimilar therapies in rheumatology\u2014\u201cO brave new world\u201d","volume":"8","author":"Scheinberg","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14712598.2014.858695","article-title":"Targeting TNF-alpha for the treatment of inflammatory bowel disease","volume":"14","author":"Billiet","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11926-012-0282-2","article-title":"Biologic therapies for spondyloarthritis: what is new?","volume":"14","author":"Baraliakos","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/imj.12292","article-title":"Biosimilars: how similar?","volume":"44","author":"Strand","year":"2014","journal-title":"Intern Med J"},{"issue":"64","key":"10.1016\/j.semarthrit.2015.04.003_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"2012","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib9","first-page":"A204","article-title":"Changing trends in IBD hospital admissions and management in England, 2001-2 to 2010-11. Poster P0270","volume":"2","author":"Ahmad","year":"2014","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.24106","article-title":"Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis","volume":"59","author":"Bejarano","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib11","first-page":"A518","article-title":"Hospitalization rate before and after anti-TNF therapy: Hospitalization rates are associated with time to anti-TNF therapy. Poster P1420","volume":"2","author":"Golovics","year":"2014","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.autrev.2013.02.005","article-title":"Is it time for biosimilars in autoimmune diseases?","volume":"12","author":"Cuadrado","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib13","first-page":"S102","article-title":"Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues","volume":"30","author":"Lapadula","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","article-title":"The role of biosimilars in the treatment of rheumatic diseases","volume":"72","author":"Dorner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s10067-012-2068-3","article-title":"Biosimilars in rheumatology: a view from Latin America","volume":"31","author":"Mysler","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/rheumatology\/ket210","article-title":"Biosimilars in rheumatology: perspective and concerns","volume":"53","author":"Scheinberg","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib17","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003517.pdf\u3009; 2005 [accessed 18.12.13]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib18","unstructured":"European Medicines Agency. European public assessment reports\u2014Biosimilars, \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter keywords&searchType=name&alreadyLoaded=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&jsenabled=false&searchGenericType=biosimilars&orderBy=authDate&pageNo=1\u3009; 2014 [accessed 22.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib19","unstructured":"World Health Organization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), \u3008http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf\u3009; 2009 [accessed 25.02.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib20","unstructured":"US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf\u3009; 2012 [accessed 21.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib21","unstructured":"US Food and Drug Administration. Guidance for industry. Quality considerations in demonstrating biosimilarity to a reference protein product, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291134.pdf\u3009; 2012 [accessed 21.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib22","unstructured":"US Food and Drug Administration. Guidance for industry. Biosimilars: questions and answers regarding implementation of the Biological Price Competition and Innovation Act of 2009, \u3008http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm259797.htm\u3009; 2012 [accessed 25.02.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib23","unstructured":"US Food and Drug Administration. Guidance for industry. Formal meetings between the FDA and biosimilar biological product sponsors or applicants, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM345649.pdf\u3009; 2013 [accessed 25.02.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib24","unstructured":"US Food and Drug Administration. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product, \u3008http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm397017.pdf\u3009; 2014 [accessed 19.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib25","unstructured":"US Food and Drug Administration. Guidance for industry. Reference product exclusivity for biological products filed under 351(a) of the PHS Act, \u3008http:\/\/www.fdanews.com\/ext\/resources\/files\/08\/08-04-14-BiosimilarsExclusivityGuidance.pdf\u3009; 2014 [accessed 19.08.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiestl","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdm345","article-title":"The challenge of biosimilars","volume":"19","author":"Mellstedt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib28","article-title":"Frontiers in nonclinical drug development: biosimilars","author":"Ryan","year":"2014","journal-title":"Vet Pathol"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2012-202941","article-title":"Biosimilars in rheumatology: the wind of change","volume":"72","author":"Schneider","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.biologicals.2011.06.024","article-title":"Clinical programs in the development of similar biotherapeutic products: rationale and general principles","volume":"39","author":"Berghout","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib31","unstructured":"European Medicines Agency. Guideline on similar biological medical products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/06\/WC500144124.pdf\u3009; 2013 [accessed 14.01.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","article-title":"Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?","volume":"16","author":"Lee","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib33","unstructured":"European Medicines Agency. Assessment report. Inflectra, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002778\/WC500151490.pdf\u3009; 2013 [accessed 08.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib34","unstructured":"European Medicines Agency. Assessment report. Remsima, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002576\/WC500151486.pdf\u3009; 2013 [accessed 09.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib35","unstructured":"Health Canada Summary basis of decision (SBD) for Inflectra, \u3008http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2014_inflectra_159493-eng.php\u3009; 2014 [accessed 09.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib36","unstructured":"Health Canada. Summary basis of decision (SBD) for Remsima, \u3008http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2014_remsima_160195-eng.php\u3009; 2014 [accessed 09.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib37","unstructured":"Biosimilar infliximab approved in Japan, but not with full extrapolation. The Biosimilarz Blog! \u3008http:\/\/www.biosimilarz.com\/?p=535\u3009; 2014 [accessed 13.01.15]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4321\/S1130-01082013000100006","article-title":"Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflammatory bowel disease","volume":"105","author":"Arguelles-Arias","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib39","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib40","unstructured":"O\u05f3Dell JR. American College of Rheumatology. Re: draft guidances relating to the development of biosimilar products; public hearing; request for comments; Docket no. FDA-2011-D-0618, \u3008http:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0CDwQFjAC&url=http%3A%2F%2Fwww.rheumatology.org%2FAdvocacy%2FLetters%2F2012%2FFDA_Biosimilar_Draft_Guidance%2F&ei=gEJFU4KrDsXL2gXEjIDoBQ&usg=AFQjCNE7WVKvF4OHsi_YlPtIx68UHeYQBg\u3009; 2012 [accessed 09.04.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/art.24560","article-title":"Impact of medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis","volume":"61","author":"Polinski","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib42","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nbt.2760","article-title":"The INN crowd","volume":"31","author":"Editorial","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib43","unstructured":"World Health Organization. 57th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 22\u201324 October 2013. Executive Summary, \u3008http:\/\/www.who.int\/medicines\/services\/inn\/57th_Executive_Summary.pdf?ua=1\u3009; 2013 [accessed 02.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib44","unstructured":"World Health Organization. International nonproprietary names, \u3008http:\/\/www.who.int\/medicines\/services\/inn\/en\/\u3009; 2014 [accessed 22.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib45","unstructured":"World Health Organization. Biological Qualifier. An INN proposal, \u3008http:\/\/www.who.int\/medicines\/services\/inn\/bq_innproposal201407.pdf\u3009; 2014 [accessed 22.12.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib46","unstructured":"American College of Rheumatology. American College of Rheumatology position statement: biosimilars, \u3008https:\/\/www.rheumatology.org\/Practice\/Clinical\/Position\/Position_Statements\/\u3009; 2011 [accessed 14.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib47","unstructured":"American Academy of Dermatology. Position statement on generic therapeutic & biosimilar substitution, \u3008http:\/\/www.aad.org\/Forms\/Policies\/Uploads\/PS\/PS-Generic%20Therapeutic%20and%20%20Biosimilar%20Substitution.pdf\u3009; 2013 [accessed 09.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/ar3310","article-title":"Biosimilars: a regulatory perspective from America","volume":"13","author":"Kay","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib49","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib50","unstructured":"Christl L. US Food and Drug Administration. FDA\u05f3s overview of the regulatory guidance for the development and approval of biosimilar products in the US, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/Biosimilars\/UCM428732.pdf\u3009; 2015 [accessed 13.01.15]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib51","first-page":"57","article-title":"Understanding and incentivizing biosimilars","volume":"64","author":"Kanter","year":"2012","journal-title":"Hastings Law J"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib52","unstructured":"Congress of the United States of America. Patient Protection and Affordable Care Act, \u3008http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-111publ148\/pdf\/PLAW-111publ148.pdf\u3009; 2010 [accessed 18.12.13]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib53","unstructured":"World Health Organization. Pharmacovigilance, \u3008http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/pharmvigi\/en\/\u3009; 2014 [accessed 14.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib54","unstructured":"US Food and Drug Administration. Guidance for industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment, \u3008http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126834.pdf\u3009; 2005 [accessed 01.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib55","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module I Pharmacovigilance systems and their quality systems, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129132.pdf\u3009; 2012 [accessed 14.05.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib56","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies\u2014non-clinical and clinical issues, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf\u3009; 2012 [accessed 19.12.13]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib57","unstructured":"European Medicines Agency. Remicade. Annex I. Summary of product characteristics, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000240\/WC500050888.pdf\u3009; 2009 [accessed 17.07.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib58","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0136","article-title":"NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives","volume":"9","author":"Zelenetz","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib59","unstructured":"Clarkston Consulting. Biosimilars are coming. Are you ready? \u3008http:\/\/www.clarkstonconsulting.com\/wp-content\/uploads\/2013\/06\/Insights_Biosimilars_US20133.pdf\u3009; 2013 [accessed 27.02.14]."},{"key":"10.1016\/j.semarthrit.2015.04.003_bib60","doi-asserted-by":"crossref","unstructured":"Danese S, Fiorino G, Michetti P. Are I.B.D. Specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members. Paper presented at 9th Congress of European Crohn\u05f3s and Colitis Organization. Copenhagen, Denmark; February 2014. P. 20\u20132.","DOI":"10.1016\/S1873-9946(14)60103-3"},{"key":"10.1016\/j.semarthrit.2015.04.003_bib61","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1590\/S0482-50042011000600013","article-title":"Opinion of some Brazilian rheumatologists about biosimilars","volume":"51","author":"Azevedo","year":"2011","journal-title":"Rev Bras Reumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T12:21:50Z","timestamp":1537705310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0049017215000657"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.04.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory diseases: Integrating biosimilars into clinical practice","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}